The Drug Administration of Vietnam under the Ministry of Health said that representative office of GlaxoSmithKline in Vietnam announced to supply around 49,000 dozes of the 6 -in-1 vaccine Infanrix Hexa for the Vietnamese market.
the amount of allocated vaccine is much lower than demand. The supplier said that the demand of acellular pertussis vaccine in the globe increased drastically for past years following the switch from whole-cell pertussis vaccines to combined acelluar pertussis vaccines in national expanded immunization programs.
Additionally, the production capability of combined acelluar pertussis vaccine manufacturers is limited.
GlaxoSmithKline promised to enhance its production effectiveness yet still maintain quality in order to meet increased demand globally. However, in 2015 and 2016, it is not able to satisfy all demand though it will supply vaccine to countries under contracts and countries which the company is mere supplier for the national expanded immunization program.
The representative office of GlaxoSmithKline in Vietnam always cooperates with Vietnamese related agencies as well as tries to find the supply sources to Vietnam.
Concerning to medical studies of 6-in-1 vaccine Hexaxim on 330 kids in the northern province of Thai Binh, the National Institute of Hygiene and Epiddemiology said that it is nearly completed. The vaccine manufactured by French Sanofi Pasteur is tested by the World Health Organization (WHO) and it is used in 80 nations.
Hexaxim is the only fully liquid, ready to use 6-in-1 vaccine to protect infants against diphtheria, tetanus, pertussis (whooping cough), Hepatitis B, poliomyelitis and invasive infections caused by Haemophilus influenzae type B.
The supplier will complete document for circulation registration in Vietnam in 2016. Hence, it is the second 6-in-1 combined acelluar pertussis vaccine which register to circulate in the Southeast Asian nation. It will be used as paid vaccine.